Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether psychological therapy changes adverse events: death ‐ at end of treatment (secondary outcome) compared with usual care and/or attention control (very low certainty).
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · adult patients after liver transplantation.
1 finding from 1 review
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review
Serious adverse events (typically more serious complications) ( · children with displaced distal radius fracture with intact or involved or displaced ulna fracture (both‐bone fracture)
It is very uncertain whether summary of findings. Surgery (percutaneous wire fixation) changes serious adverse events (typically more serious complications) ( compared with not surgery (cast only) (very low certainty).
1 finding from 1 review
Adverse events ‐ incidents of unspecified severe adverse events · Adults with co‐morbid PTSD and SMI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome: adverse events (skin sensitisation at 2 months) · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Adverse events: Dysphagia‐related complications Occurrence of dysphagia‐related complications: pneumonia, dehydration, mucositis and oral yeast infection · adults with advanced head and neck cancer
1 finding from 1 review
Side effects or other adverse events · adults with antisocial personality disorder
1 finding from 1 review
Infants with possible related Severe Adverse Events ‐ 24 months11 · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP regimen administered to infants for 14 weeks changes infants with possible related Severe Adverse Events ‐ 24 months11 compared with sdNVP plus ZDV (1week) (very low certainty).
1 finding from 1 review
Primary: adverse events ‐ reported adverse events, mainly erythema · people with hand eczema unresponsive to clobetasol propionate
Irradiation with UV light: local narrow‐band UVB probably leads to higher primary: adverse events ‐ reported adverse events, mainly erythema compared with local PUVA (moderate certainty).
1 finding from 1 review
Adverse effects: headache · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events participant and study investigator reported · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in serious adverse events participant and study investigator reported compared with skim milk & lactose powder (low certainty).
1 finding from 1 review
Adverse events: including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash · people with sickle cell disease
1 finding from 1 review
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment — not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: General‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
1 finding from 1 review
Mothers with Severe Adverse Events Requiring Treatment Modification · HIV‐infected mothers and their breastfeeding infants
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes mothers with Severe Adverse Events Requiring Treatment Modification compared with an extended ZDV/3TC/ABC administered to mothers (very low certainty).
1 finding from 1 review
Adverse events ‐ incidents of unspecified severe events ‐ medium term · Adults with co‐morbid PTSD and SMI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).
1 finding from 1 review